Abstract | BACKGROUND: CASE REPORT: We report the successful use of exenatide, combined with insulin, in a 66-year-old woman initially diagnosed with Type 2 diabetes in 1989 but now exhibiting a Type 1 phenotype. Diet, lifestyle advice and oral glucose-lowering agents were commenced but persisting poor control necessitated insulin therapy in 2005. She later presented twice in diabetic ketoacidosis, suggesting conversion to a Type 1 phenotype (postprandial C-peptide < 94 pmol/l). Despite differing insulin regimens, control remained poor with frequent hyperglycaemic and hypoglycaemic excursions, severely impairing quality of life. Whilst an inpatient in 2007 [glycated haemoglobin (HbA(1c)) 10.2%, body mass index (BMI) 31.5 kg/m(2)] exenatide was commenced in an attempt to stabilize glycaemic control. Dramatic improvements were seen and continued. Eight months later, HbA(1c) had fallen by 2% with an 8-kg weight loss and 10-unit reduction in daily insulin dose. Quality of life dramatically improved. C-peptide remains undetectable. CONCLUSIONS:
|
Authors | A N Paisley, M W Savage, P G Wiles |
Journal | Diabetic medicine : a journal of the British Diabetic Association
(Diabet Med)
Vol. 26
Issue 9
Pg. 935-8
(Sep 2009)
ISSN: 1464-5491 [Electronic] England |
PMID | 19719716
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- C-Peptide
- Hypoglycemic Agents
- Peptides
- Venoms
- Exenatide
|
Topics |
- Aged
- C-Peptide
(metabolism)
- Diabetes Mellitus, Type 1
(drug therapy, etiology)
- Diabetes Mellitus, Type 2
(complications, drug therapy)
- Exenatide
- Female
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Overweight
(complications)
- Peptides
(therapeutic use)
- Treatment Outcome
- Venoms
(therapeutic use)
|